ABSTRACT Background Identifying predictive and monitoring biomarkers for allergen immunotherapy response is crucial for enhancing clinical efficacy. This study aims to investigate the systemic and local levels of immunoglobulins and identify potential biomarkers in house dust mite (HDM) allergic rhinitis (AR) patients who are undergoing subcutaneous ...
Xu Xu +6 more
wiley +1 more source
p53 regulates early mucosal immunity via antigen presentation in zebrafish intestine post-SVCV vaccination. [PDF]
Zhao Z +6 more
europepmc +1 more source
Dupilumab Beyond the Airway: Decreased Morbidity in a Real‐World Analysis
ABSTRACT Background Post hoc analyses of clinical trials have characterized dupilumab's adverse effects, yet the real‐world impact in chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma is not well described. This study aims to characterize the risks of lymphoma, cardiovascular events, eosinophilia, joint pain, inflammatory arthritis, and ...
Emma J. Anisman +9 more
wiley +1 more source
Correction: Immunoenhancing effects of Gynostemma Pentaphyllum Extract on mucosal immunity against porcine epidemic diarrhea virus. [PDF]
Zhang Y +7 more
europepmc +1 more source
ABSTRACT Background Although shifts in nasal microbiota have been well‐documented in inflammatory upper airway conditions, microbiota tumor‐associated alterations remain uncharacterized. This study is the first to compare sinonasal microbiota profiles of patients with malignant tumors (MT), benign tumors (BT), and controls, offering insights into tumor‐
Evan A. Patel +13 more
wiley +1 more source
Editorial: The role of bioactive compounds and nutrients in intestinal mucosal immunity, liver and vascular inflammation. [PDF]
Sun F, Ruan Z, Abedelmaksoud TG.
europepmc +1 more source
Dosing Interval Extension of Dupilumab in CRSwNP: Five‐Year Real World Outcomes
ABSTRACT Background Chronic rhinosinusitis with nasal polyps (CRSwNP) is a persistent, often Type 2‐mediated inflammatory disease that markedly impairs quality of life. While dupilumab provides rapid improvement, there is limited evidence on long‐term outcomes beyond 2 years, and the clinical impact of dosing‐interval extension remains unclear.
Nicholas J. Campion +15 more
wiley +1 more source
Editorial: Advances in understanding mucosal immunity in coronaviruses: from mechanisms to vaccines. [PDF]
Afrin F +3 more
europepmc +1 more source
Uncovering Cystic Fibrosis Carrier: Insights From a Heterozygous CFTR‐F508del Rabbit Model
ABSTRACT Background Chronic rhinosinusitis (CRS) is a heterogeneous inflammatory disorder frequently associated with impaired mucociliary clearance and bacterial infection. Individuals carrying a single cystic fibrosis transmembrane conductance regulator (CFTR) mutation exhibit partial CFTR dysfunction and are increasingly recognized as being at risk ...
Do‐Yeon Cho +9 more
wiley +1 more source
Fibrinogen-Like Protein 2 Modulates B Cell Mucosal Immunity by Suppressing Receptor for Activated C-Kinase 1-Mediated AKT Phosphorylation. [PDF]
Chang J +10 more
europepmc +1 more source

